Table 2.

Selective clinical trials of AR signaling inhibitors

Drug	Target	Condition	Status	Phase	NCT identifier
Degarelix	GnRHR	PCa	Completed	3	NCT00451958
Degarelix	GnRHR	PCa	Completed	3	NCT01071915
Degarelix	GnRHR	PCa	Completed	3	NCT02015871
Relugolix	GnRHR	PCa	Recruiting	3	NCT05050084
Relugolix	GnRHR	PCa	Completed	3	NCT03085095
Abarelix	GnRHR	PCa	Completed	3	NCT00841113
Leuprolide	GnRHR	PCa	Completed	4	NCT00220194
Leuprolide	GnRHR	PCa	Recruiting	3	NCT04914195
Goserelin	GnRHR	PCa	Completed	3	NCT00439751
Goserelin	GnRHR	PCa	Not yet recruiting	4	NCT03971110
Triptorelin	GnRHR	PCa	Completed	3	NCT01715129
Triptorelin	GnRHR	PCa	Completed	3	NCT00104741
Histrelin	GnRHR	Metastatic PCa	Recruiting	2/3	NCT04787744
Histrelin	GnRHR	PCa	Completed	3	NCT01697384
Buserelin	GnRHR	PCa	Completed	3	NCT00003653
Buserelin	GnRHR	PCa	Recruiting	3	NCT05050084
Enzalutamide	AR	CRPC	Completed	3	NCT00974311
Enzalutamide	AR	mCRPC	Completed	4	NCT02116582
Enzalutamide	AR	mCRPC	Completed	4	NCT02485691
Apalutamide	AR	PCa	Completed	2	NCT01790126
Apalutamide	AR	Nonmetastatic CRPC	Recruiting	3	NCT04108208
Darolutamide	AR	PCa	Not yet recruiting	3	NCT02799602
Darolutamide	AR	Nonmetastatic CRPC	Completed	3	NCT02200614
ARV-110	AR	mCRPC	Recruiting	1/2	NCT03888612
Abiraterone	CYP17A1	mCRPC	Completed	3	NCT04056754
Abiraterone	CYP17A1	mCRPC	Completed	3	NCT00887198
Abiraterone	CYP17A1	mCRPC	Completed	3	NCT02111577
Seviteronel	CYP17A1	CRPC	Completed	2	NCT02445976
Orteronel	CYP17A1	mCRPC	Completed	3	NCT01193257
Galeterone	CYP17A1	CRPC	Completed	2	NCT01709734